A5023671070- Myasthenia Gravis and Thymoma
- Pituitary Gland Disorders and Treatments
- Neuroblastoma Research and Treatments
- Neuroendocrine Tumor Research Advances
- Testicular diseases and treatments
- Adrenal and Paraganglionic Tumors
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Glioma Diagnosis and Treatment
- Urologic and reproductive health conditions
- Lymphoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Genital Health and Disease
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Histiocytic Disorders and Treatments
- Gastrointestinal Tumor Research and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Multiple Myeloma Research and Treatments
Regione Campania
2015-2024
Federico II University Hospital
2011-2024
University of Naples Federico II
2012-2022
Humanitas University
2017
Università Cattolica del Sacro Cuore
2016
National Agency for New Technologies, Energy and Sustainable Economic Development
2016
McMaster University
2016
Nuovo Ospedale San Giovanni di Dio
2016
Bambino Gesù Children's Hospital
2014
Spanish Oncology Genitourinary Group
2012
Purpose No effective salvage treatments are available for patients with advanced/recurrent thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based chemotherapy. This study evaluated the activity of everolimus in T TC previously treated cisplatin-containing Patients and Methods was a single-arm, single-stage, open-label, multicenter, phase II trial. received oral 10 mg/d until disease progression, unacceptable toxicity, patient refusal. A Fleming trial designed. The null...
No previous prospective trials have been reported with sorafenib in patients sunitinib-refractory metastatic renal cell cancer (MRCC). We conducted a multicenter study to determine the activity and tolerability of as second-line therapy after sunitinib progression MRCC.Between January 2006 September 2008, 52 were enrolled onto this single-arm phase II study. All received 400 mg orally twice day until disease or intolerable toxicity. The primary end point was objective response rate (complete...
Radioactive iodine is a crucial tool for treatment of differentiated thyroid cancer (DTC). In 5% cases, DTCs lose I-131 avidity and assume an aggressive behaviour. Treatment options iodine-refractory DTC are limited. We report the experience off-label use tyrosine kinase inhibitor sorafenib advanced DTC.Patients with progressive refractory to radioactive were treated used independently from their performance status. Primary study end-points radiological response, progression-free survival...
What's known on the subject? and What does study add? Metastatic or locally advanced squamous cell carcinoma of penis (SCCP) is generally incurable, but it can be palliated with systemic chemotherapy. Two retrospective studies, involving <10 patients each, showed that cisplatin plus continuous infusion 5-fluorouracil (5-FU) may effective well tolerated. Cisplatin, methotrexate bleomycin, irinotecan taxanes also play an important role for advanced/metastatic SCCP. Finally, anti-EGFR therapy...
Thymomas are rare epithelial neoplasms frequently associated with myasthenia gravis, hypogammaglobulinemia, and pure red-cell aplasia.1–11 In aplasia, autoantibodies against early late erythroid-cell progenitors or erythropoietin, as well inhibitory cellular immune mechanisms, have been implicated.9–11 Limited information suggests that patients aplasia thymoma a poor prognosis.6,7,10 We recently demonstrated high uptake of indium-labeled octreotide (111In-DTPA-d-Phe1-octreotide) in thymomas,...
Abstract BACKGROUND Therapeutic options to cure advanced, recurrent, and metastatic thymic tumors are limited. Evidence of a high uptake indium‐labeled octreotide ( 111 In‐DTPA‐ D ‐Phe 1 ‐octreotide) in the curative application somatostatin analogs prednisone one patient with thymoma pure red cell aplasia led authors start Phase II study. METHODS Sixteen patients advanced tumors, unresponsive conventional chemotherapeutic regimens, were enrolled The schedule includes administration analog...
To determine the activity and tolerability of docetaxel re-treatment after first-line therapy with in castration-resistant prostate cancer (CRPC).Between November 2005 January 2009, 45 patients initially responding to then experiencing disease progression a period biochemical remission at least 5 months were enrolled prospective multicenter study re-treated docetaxel. The primary endpoint was response (biochemical partial defined as > 50% prostate-specific antigen [PSA] decline); secondary...
We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment women metastatic breast cancer (MBC). In total, 41 patients MBC were enrolled therapy study oral gefitinib (250 mg day−1) intravenous (75 m−2, first 14 patients; or 100 following 27 patients, on day 1 3-week cycle). Out 38 received at least one cycle therapy. There no differences tolerability between...
Advanced chemorefractory thymic epithelial tumors still represent a challenge in clinical oncology. A rationale-based therapeutic approach targeting key pathway should the ideal solution neoplasm that can over-express Epidermal Growth Factor Receptor (EGFR) component. On basis of these considerations, two patients with metastatic heavily pretreated disease were evaluated for EGFR expression primitive tumor, being considered this data as an anti treatment monoclonal antibody cetuximab which...
The coronavirus disease 2019 (COVID-19) pandemic has become a public health emergency affecting frail populations, including patients with cancer. This poses the question of whether cancer treatments can be postponed or modified without compromising their efficacy, especially for highly curable cancers such as germ cell tumors (GCTs).To depict state-of-the-art management GCTs during COVID-19 pandemic, survey 26 questions was circulated by e-mail among physicians belonging to three...
High levels of somatostatin receptor subtype 2 (SSTR2) are a prerequisite for therapy with unlabeled or labeled analogs. However, it is still unclear how the heterogeneity SSTR2 expression may affect tumor response to therapy. The aim our study was test ability an imaging parameter such as coefficient variation (CoV) derived from PET/CT 68Ga-peptides in evaluation and quantification within primary metastatic lesions patients neuroendocrine tumors. Methods: Thirty-eight pathologically proven...
Abstract Objectives Thymic epithelial tumors (TET) patients are at high risk of autoimmune and hypoimmune complications. Limited evidence is available on the potential immune-related inflammatory reactions induced by SARS-Cov-2 vaccine in this patient population. Methods In order to identify subjects higher for complications, we prospectively evaluated a panel serum biomarkers related inflammation (TNF-α, IL-1β, −6, −10, −12, −17A, IFN-α, β γ, MPO, MMP-9), vascular damage (E- P-selectin,...
This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel.Patients were enrolled from March 2011 December an international expanded access program. In January 2012, when cabazitaxel became commercially available, a prospective was initiated at University Federico II of Naples and Rionero Vulture Hospital.Forty-seven this study. Patients received median nine cycles cabazitaxel. Median progression-free survival 7.0...